Fixed combination isosorbide dinitrate - Hydralazine for nitric-oxide-enhancing therapy in heart failure

Expert Opinion on Pharmacotherapy

Volumn 7, Issue 18, 2006, Pages 2521-2531

  Franciosa, Joseph A ^a  

^a NONE   (United States)

Author keywords

African American; Ethnicity; Heart failure; Hydralazine; Isosorbide dinitrate; Nitric oxide

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUCINDOLOL; CARVEDILOL; CYTOKINE RECEPTOR ANTAGONIST; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; ENDOTHELIN RECEPTOR ANTAGONIST; HYDRALAZINE; HYDRALAZINE PLUS ISOSORBIDE DINITRATE; ISOSORBIDE DINITRATE; METOPROLOL; NITRATE; PLACEBO; PRAZOSIN; PROTEINASE INHIBITOR;

AFRICAN AMERICAN; ANGINA PECTORIS; CLINICAL TRIAL; DIZZINESS; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG POTENTIATION; DRUG STRUCTURE; EPIDEMIC; ETHNIC GROUP; HEART FAILURE; HEART PALPITATION; HUMAN; HYPERTENSION; HYPOTENSION; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; REVIEW; SINGLE DRUG DOSE; SYNCOPE; TACHYCARDIA;

CARDIAC OUTPUT, LOW; DRUG COMBINATIONS; HEART FAILURE, CONGESTIVE; HUMANS; HYDRALAZINE; ISOSORBIDE DINITRATE; NITRIC OXIDE; NITRIC OXIDE DONORS;

EID: 33845657814     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.7.18.2521     Document Type: Review

References (75)

1. AMERICAN HEART ASSOCIATION: Heart Disease and Stroke Statistics:2005 Update. Dallas, TX; American Heart Association; 2005.
2. MASOUDI FA, HAVRANEK EP, KRUMHOLZ HM: The burden of chronic congestive heart failure in older persons: magnitude and implications for policy and research. Heart Fail. Rev. (2002) 7(1):9-16
3. HUNT SA, ABRAHAM WF, CHIN MH et al.: American College of Cardiology (ACC); American Heart Association (AHA) Task Force on Practice Guidelines; American College of Chest Physicians; International Society for Heart and Lung Transplantation; Heart Rhythm Society. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation (2005) 112(12):e154-e235.
4. ADAMS KF, LINDENFELD J, ARNOLD JMO et al.: HFSA 2006 Comprehensive Heart Failure Practice Guideline. J. Card. Fail. (2006) 12(1):e1-e122.
5. CHOBANIAN AV, BAKRIS GL, BLACK HR et al.: Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension (2003) 42(6):1206-1252.
6. YANCY CW: Heart failure in African Americans: a cardiovascular enigma. J. Card Fail. (2000) 6(3):183-186.
7. UNDERWOOD PL, MITCHELL J, TAYLOR AL, TAYLOR MP: Rationale for a change in management strategies for the African American with heart failure. ABC Digest of Urban Cardiology. Nov/Dec 2005:12-22.
8. YANCY CW, STRONG M. The natural history, epidemiology, and prognosis of heart failure in African Americans. Congest. Heart Fail. (2004) 10(1):15-18.
9. TAYLOR AL, ZIESCHE S, YANCY C et al.: Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N. Engl. J. Med. (2004) 351(20):2049-2057.
10. THE DIGITALIS INVESTIGATION GROUP: The effect of digoxin oh mortality and morbidity in patients with heart failure. N. Engl. J. Med. (1997) 336(8):525-533.
11. FRANCIOSA JA, WILEN M, ZIESCHE S, COHN JN: Survival in men with severe chronic left ventricular failure due to either coronary heart disease or to idiopathic dilated cardiomyopathy. Am. J. Cardiol. (1983) 51(5):831-836.
12. GUIHA NH, COHN JN, MIKULIC E, FRANCIOSA JA, LIMAS CJ: Treatment of refractory heart failure with infusion of nitroprusside. N. Engl. J. Med. (1974) 291(12):587-592.
13. COHN JN: Vasodilator therapy for heart failure. The influence of impedance on left ventricular performance. Circulation. 1973 48(1):5-8.
14. FRANCIOSA JA: The potential role of community-based registries to complement the limited applicability of clinical trial results to the community setting: heart failure as an example. Am. J. Manag. Care (2004) 10(7 Part 2):487-492.
15. HOGG K, SWEDBERG K, MCMURRAY J. Heart failure with preserved left ventricular systolic function; epidemiology, clinical characteristics, and prognosis. J. Am. Coll. Cardiol. (2004) 43(3):317-327.
16. ANSARI M, ALEXANDER M, TUTAR A et al.: Incident cases of heart failure in a community cohort: importance and outcomes of patients with preserved systolic function. Am. Heart J. (2003) 146(1):115-120.
17. MASOUDI FA, HAVRANEK EP, SMITH G et al.: Gender, age, and heart failure with preserved left ventricular systolic function. J. Am. Coll. Cardiol. (2003) 41(2):217-223.
18. MCCULLOUGH PA, PHILBIN EF, SPERTUS JA, KAATZ S, SANDBERG KR, WEAVER WD: Confirmation of a heart failure epidemic: findings from the Resource Utilization Among Congestive Heart Failure (REACH) study. J. Am. Coll. Cardiol. (2002) 39(1):60-69.
19. KHAND A, GEMMEL I, CLARK AL, CLELAND JGF: Is the prognosis of heart failure improving? J. Am. Coll. Cardiol. (2000) 36(7):2284-2286.
20. SENNI M, TRIBOUILLOY CM, RODEHEFFER RJ et al.: Congestive heart failure in the community. Trends in incidence and survival in a 10-year period. Arch. Intern. Med. (1999) 159(1):29-34.
21. TUNIS SR, STRYER DB, CLANCY CM: Practical clinical trials. Increasing the value of clinical research for decision making in clinical and health policy. J.A.M.A. (2003) 290(12):1624-1632.
22. WELLS KB: Treatment research at the crossroads: the scientific interface of clinical trials and effectiveness research. Am. J. Psychiatry (1999) 156(1):5-10.
23. YANCY CW, FOWLER MB, COLUCCI WS et al.: US Carvedilol Heart Failure Study Group. Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure. N. Engl. J. Med. (2001) 344(18):1358-1365.
24. WILSON PW: From hypertension to heart failure: what have we learned? Clin. Cardiol. (1999) 22(Suppl. 5):V1-V10.
25. FLACK JM, FERDINAND KG, NASSER SA: Epidemiology of hypertension and cardiovascular disease in African Americans. J. Clin. Hypertens. (2003) 5(1 Suppl. 1):5-11.
26. NESBITT S, VICTOR RG: Pathogenesis of hypertension in African Americans. Congest. Heart Fail. (2004) 10(1):24-29.
27. LOSCALZO J, WELCH G: Nitric oxide and the cardiovascular system. Prog. Cardiovasc. Dis. (1995) 38(2):87-104.
28. VITA JA: Nitric oxide and vascular reactivity in African American patients with hypertension. J. Card. Fail. (2003) 9:(5 Suppl. Nitric Oxide):S199-S204.
29. CARDILLO C, KILCOYNE CM, CANNON RO, PANZA JA: Racial differences in nitric oxide-mediated vasodilator response to mental stress in the forearm circulation. Hypertension (1998) 31(6):1235-1239.
30. KATZ SD, HRYNIEWICZ K, HRILJAC I et al.: Vascular endothelial dysfunction and mortality risk in patients with chronic heart failure. Circulation (2005) 111(3):310-314.
31. KELSEY RM, ALPERT BS, PATTERSON SM, BARNARD M: Racial differences in hemodynamic responses to environmental thermal stress among adolescents. Circulation. (2000) 101(19):2284-2289.
32. WEIR MR, GRAY JM, PASTER R, SAUNDERS E: Differing mechanisms of action of angiotensin-converting enzyme inhibition in black and white hypertensive patients. The Trandolapril Multicenter Study Group. Hypertension. (1995) 26(1):124-130.
33. COHN JN, LOSCALZO J, FRANCIOSA JA: Nitric oxide's role in heart failure: pathophysiology and treatment. Introduction. J. Card. Fail. (2003) 9(Suppl. 5 Nitric Oxide):S197-S119.
34. EXNER DV, DRIES DL, DOMANSKI MJ, COHN JN: Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N. Engl. J. Med. (2001) 344(18):1351-1357.
35. COHN JN, ARCHIBALD DG, ZIESCHE S et al.: Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of a Veterans Administration Cooperative Study. N. Engl. J. Med. (1986) 314(24):1547-1552.
36. COHN JN, JOHNSON G, ZIESCHE S et al.: A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N. Engl. J. Med. (1991) 325(5):303-310.
37. CARSON P, ZIESCHE S. JOHNSON G, COHN JN: Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group. J. Card. Fail. (1999) 5(3):178-187.
38. FRANCIOSA JA, MASSIE BM, LUKAS MA et al., for the COHERE Participant Physicians: β-blocker therapy for heart failure outside the clinical trial setting: findings of a community-based registry. Am. Heart J. (2004) 148(4):718-726.
39. STAFFORD RS, RADLEY DC: The underutilization of cardiac medications of proven benefit, 1990 to 2002. J. Am. Coll. Cardiol. (2003) 41(1):56-61.
40. GUPTA R, TANG WH, YOUNG JB: Patterns of β-blocker utilization in patients with chronic heart failure: experience from a specialized outpatient heart failure clinic. Am. Heart J. (2004) 147(1):79-83.
41. MAGGIONI AP, SINAGRA G, OPASICH C et al.: Treatment of chronic heart failure with beta adrenergic blockade beyond controlled clinical trials: the BRING-UP experience. Heart. (2003) 89(3):299-305
42. MEHTA PA, MCDONAGH S, POOLE-WILSON PA, GROCOTT-MASON R, DUBREY SW: Heart failure in a district general hospital: are target doses of beta-blockers realistic? Q. J. Med. (2004) 97(3):133-139.
43. MEHRA MR, UBER PA, FRANCIS GS: Heart failure therapy at a crossroad: are there limits to the neurohormonal model? J. Am. Coll. Cardiol. (2003) 41(9):1606-1610.
44. PAR PHARMACEUTICALS. Hydralazine Hydrochloride Tablets. Product Labeling, June 2001.
45. ISORDIL® (isosorbide dinitrate) Titradose® Tablets. Product Labeling, Feb. 17, 1999
46. HARE JM: Nitroso-redox balance in the cardiovascular system. N. Engl. J. Med. (2004) 351(20):2112-2114.
47. MALINSKI T: Understanding nitric oxide physiology in the heart: a nanomedical approach. Am. J. Cardiol. (2005) 96(Suppl.7B): 13i-24i.
48. LI R, LYN D, LAPU-BULA R et al.: Relation of endothelial nitric oxide synthase gene to plasma nitric oxide level, endothelial function, and blood pressure in African Americans. Am. J. Hypertens. (2004) 17(7):560-567.
49. RAUHALA P, CHIUEH CC: Effects of atypical antioxidative agents, S-nitrosoglutathione and manganese, on brain lipid peroxidation induced by iron leaking from tissue disruption. Ann. NY Acad. Sci. (2000) 899:238-254.
50. MUNZEL T, KURZ S, RAJAGOPALAN S et al.: Hydralazine prevents nitroglycerin tolerance by inhibiting activation of a membrane-bound NADH oxidase: a new action for an old drug. J. Clin. Invest. (1996) 98(6):1465-1470.
51. GOGIA H, MEHRA A, PARIKH S et al.: Prevention of tolerance to hemodynamic effects of nitrates with concomitant use of hydralazine in patients with chronic heart failure. J. Am. Coll. Cardiol. (1995) 26(7):1575-1580.
52. KALINOWSKI L, DOBRUCKI IT, MALINSKI T: Race-specific differences in endothelial function: predisposition of African Americans to vascular diseases. Circulation (2004) 109(21):2511-2517
53. GATTAS GJ, KATO M, SOARES-VIEIRA JA et al.: Ethnicity and glutathione S-transferase (GSTM1/GSTT1) polymorphisms in a Brazilian population. Braz. J. Med. Biol. Res. (2004) 37(4):451-458.
54. NITROMED, Inc. BiDil. Product Labeling, 2005.
55. FRANCIOSA JA, MIKULIC E, COHN JN, JOSE E, FABIE A: Hemodynamic effects of orally administered isosorbide dinitrate in patients with congestive heart failure. Circulation (1974) 50(5):1020-1024.
56. FRANCIOSA JA, PIERPONT G, COHN JN: Hemodynamic improvement after oral hydralazine in left ventricular failure. Ann. Intern. Med. (1977) 86(4):388-393.
57. FRANCIOSA JA, WEBER KT, LEVINE TB et al.: Hydralazine in the long-term treatment of chronic heart failure: lack of difference from placebo. Am. Heart J. (1982) 104(3):587-594.
58. CONRADSON TB, RYDEN L, AHLMARK G et al.: Clinical efficacy of hydralazine in chronic heart failure: one-year double-blind placebo-controlled study. Am. Heart. J. (1984) 108(4 Part 1):1001-1006.
59. FRANCIOSA JA, COHN JN: Efficacy of long-term nitrate treatment in chronic left ventricular failure. In Nitrates III. Lichtlen P, Engel HJ, Schrey A, Swan HJC: (Eds). Springer-Verlag. Berlin (1981):510-515.
60. LEWIS BS, RABINOWITZ B, SCHLESINGER Z et al.: Effect of isosorbide-5-mononitrate on exercise performance and clinical status in patients with congestive heart failure. Results of the Nitrates in Congestive Heart Failure (NICE) Study. Cardiology(1999) 91(1):1-7.
61. FRANCIOSA JA, COHN JN: Sustained hemodynamic effects without tolerance during long-term isosorbide dinitrate treatment of chronic left ventricular failure. Am. J. Cardiol. (1980) 45(3):648-654.
62. PIERPONT G, COHN JN, FRANCIOSA JA: Combined oral hydralazine-nitrate therapy in left ventricular failure. Hemodynamic equivalence to sodium nitroprusside. Chest (1978) 73(1):8-13.
63. FRANCIOSA JA, TAYLOR AL, COHN JN et al., for the A-HeFT investigators: African-American heart failure trial (A-HeFT): rationale, design, and methodology. J. Card. Fail. (2002) 8(3):128-135.
64. SCHWARTZ RS: Racial profiling in medical research. N. Engl. J. Med. (2001) 344(18):1392-1393.
65. TAYLOR HA: Capacity building for research in minority health. Am. J. Med. Sci. (2001) 322(5):241-242.
66. PEARSON TA: Capacity for research in minority health: the need for infrastructure plus will. Am. J. Med. Sci. (2001) 322(5):243-247.
67. BECKER DM, TUGGLE MB, PRENTICE MF: Building a gateway to promote cardiovascular health research in African-American communities: lessons and findings from the field. Am. J. Med. Sci. (2001) 322(5):276-281.
68. HASSABALLA H, GORELICK PB, WEST CP, HANSEN MD, ADAMS HP: Ischemic stroke outcome: racial differences in the trial of danaparoid in acute stroke (TOAST). Neurology. (2001) 57(4):691-697.
69. YANCY CW: Heart failure in blacks: etiologic and epidemiologic differences. Curr. Cardiol. Rep. (2001) 3(3):191-197.
70. TAYLOR AL, COHN JN, WORCEL M, FRANCIOSA JA, for the A-HeFT Investigators. The African-American Heart Failure Trial (A-Heft): Background, Rationale and Significance. J. Natl. Med. Assoc. (2002) 94(9):762-769
71. SCHUNKERT H, HENSE HW, HOLMER SR et al.: Association between a deletion polymorphism of the angiotensin-converting-enzyme gene and left ventricular hypertrophy. N. Engl. J. Med. (1994) 330(23):1634-1638.
72. MYERSON SG, MONTGOMERY HE, WHITTINGHAM M et al.: Left ventricular hypertrophy with exercise and ACE gene insertion/deletion polymorphism: a randomized controlled trial with losartan. Circulation (2001) 103(2):226-230.
73. RAYNOLDS MV, BRISTOW MR, BUSH EW et al.: Angiotensin-converting enzyme DD genotype in patients with ischaemic or idiopathic dilated cardiomyopathy. Lancet. (1993) 342(8879):1073-1075.
74. ERGUL S, PARISH DC, PUETT D, ERGUL A: Racial differences in plasma endothelin-1 concentrations in individuals with essential hypertension. Hypertension. (1996) 28(4):652-655.
75. GRUBBS AL, ANSTADT MP, ERGUL A: Saphenous vein endothelin system expression and activity in African American patients. Arterioscler. Thromb. Vasc. Biol. (2002) 22(7):1122-1127.